AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/1102
Title: The perioperative administration of dexamethasone and infection (PADDI) trial protocol: rationale and design of a pragmatic multicentre non-inferiority study
Authors: Corcoran Tomas B
Myles Paul S
Forbes Andrew B
O'Loughlin Ed
Leslie Kate
Story David
Short Timothy G
Chan Matthew TV
Coutts Pauline
Sidhu Jasprett
Cheng Allen C
Bach Leon A
Ho Kwok M
Australian and New Zealand College of Anaesthetists Clinical Trials Network (ANZCA)
Australian Society for Infectious Diseases (ASID) Clinical Research Network
ANZCA/FPM Author: ANZCA Clinical Trials Network
Chan, MTV
Corcoran, T
Ho, KM
Leslie, K
Myles, PS
O'Loughlin, E
Short, TG
Story, DA
Anzca Brief Name: Australian Society for Infectious Diseases (ASID) Clinical Research Network
Keywords: Dexamethasone
Diabetes
Postoperative Nausea and Vomiting
Surgical Wound Infection
glucocorticoid
Citation: 2019 Sep 6;9(9):e030402.
Abstract: Introduction: The intraoperative administration of dexamethasone for prophylaxis against postoperative nausea and vomiting is a common and recommended practice. The safety of the administration of this immunosuppressive agent at a time of significant immunological disruption has not been rigorously evaluated in terms of infective complications. Methods/analysis: This is a pragmatic, multicentre, randomised, controlled, non-inferiority trial. A total of 8880 patients undergoing elective major surgery will be enrolled. Participants will be randomly allocated to receive either dexamethasone 8 mg or placebo intravenously following the induction of anaesthesia in a 1:1 ratio, stratified by centre and diabetes status. Patient enrolment into the trial is ongoing. The primary outcome is surgical site infection at 30 days following surgery, defined according to the Centre for Disease Control criteria. Ethics/dissemination: The PADDI trial has been approved by the ethics committees of over 45 participating sites in Australia, New Zealand, Hong Kong, South Africa and the Netherlands. The trial has been endorsed by the Australia and New Zealand College of Anaesthetists Clinical Trials Network and the Australian Society for Infectious Diseases Clinical Research Network. Participant recruitment began in March 2016 and is expected to be complete in mid-2019. Publication of the results of the PADDI trial is anticipated to occur in early 2020. Trial registration number: ACTRN12614001226695.
URI: http://hdl.handle.net/11055/1102
DOI: 10.1136/bmjopen-2019-030402
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/31494615/
ISSN: 2044-6055
Journal Title: BMJ Open
Type: Journal Article
Study/Trial: Case Control Studies
Appears in Collections:Scholarly and Clinical

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.